OxyMask for delivering oxygen therapy: Medtech innovation briefing [MIB160] – NICE

NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy. The technology described in this briefing is OxyMask. It is used for delivering oxygen therapy. The innovative aspect is the novel design, which is intended to improve the efficiency and

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia: Technology appraisal guidance [TA541] – NICE

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia

Neuropad for detecting preclinical diabetic peripheral neuropathy: Medical technologies guidance [MTG38] – NICE

The case for adopting Neuropad to detect preclinical diabetic peripheral neuropathy is not supported by the evidence. Neuropad detects sub-normal sweating in patients with diabetes but the clinical importance of this in current NHS care pathways is poorly defined. There

The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs: Medtech innovation briefing [MIB159] – NICE

The technology described in this briefing is The Vest. It is intended to deliver high-frequency chest wall oscillation for clearing airways. The focus of this briefing is its use in adults and children with complex neurological needs, such as cerebral palsy and

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: Technology appraisal guidance [TA540]

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults. Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin. Pembrolizumab

Leadless cardiac pacemaker implantation for bradyarrhythmias: Interventional procedures guidance [IPG626] – NICE

Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias in adults. This involves inserting a device into the heart that helps it beat at a normal rate. Evidence on the safety of leadless cardiac pacemaker implantation for bradyarrhythmias shows that

Superior rectal artery embolisation for haemorrhoids: Interventional procedures guidance [IPG627] – NICE

Evidence-based recommendations on superior rectal artery embolisation for haemorrhoids in adults. This involves blocking the blood vessels supplying the haemorrhoids with tiny plastic particles or metal coils. Current evidence on the safety and efficacy of superior rectal artery embolisation for

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours: Technology appraisal guidance [TA539] – NICE

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults. Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive

Neon EEG electrode for EEG monitoring in newborns: Medtech innovation briefing [MIB155] – NICE

The technology described in this briefing is Neon EEG electrode. It is used for electroencephalogram (EEG) monitoring in newborns. The innovative aspects are that EEG electrodes can be placed on a newborn, without extra preparation or an EEG technician. The intended place in therapy would be

NephroCheck test to help assess the risk of acute kidney injury in critically ill patients: Medtech innovation briefing [MIB156] – NICE

The technology described in this briefing is the NephroCheck (including VITROS NephroCheck) test. It is an in vitro diagnostic test used to measure urinary biomarkers of kidney injury as an aid in detecting acute kidney injury. The innovative aspects are that NephroCheck is claimed

AlignRT in breast cancer radiotherapy: Medtech innovation briefing [MIB157] – NICE

The technology described in this briefing is the AlignRT patient position monitoring system. This briefing focuses on its use during breast cancer radiation therapy. The innovative aspect is that it may avoid inaccurate treatment by precisely tracking a patient’s position

Rezum for treating benign prostatic hyperplasia: Medtech innovation briefing [MIB158] – NICE

The technology described in this briefing is Rezum, which uses steam to ablate prostate tissue with the aim of improving lower urinary tract symptoms secondary to benign prostatic hyperplasia. The innovative aspects are that the company claims that it is quicker to do than

Dinutuximab beta for treating neuroblastoma: Technology appraisal guidance [TA538] – NICE

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over. Recommendations Dinutuximab beta is recommended as an option for treating high-risk neuroblastoma in people aged 12 months and over whose disease has at least

Remote ECG interpretation consultancy services for cardiovascular disease: Medtech innovation briefing [MIB152] – NICE

The technologies described in this briefing are remote electrocardiogram (ECG) interpretation consultancy services. They are used for assisting in diagnosing and decision-making for people with cardiovascular disease. The innovative aspects are that with remote ECG interpretation, a person does not need to travel

Mechanical thrombectomy devices for acute ischaemic stroke: Medtech innovation briefing [MIB153] – NICE

Thetechnologies described in this briefing are 21 mechanical thrombectomy devices of 2 types: stent retrievers and aspiration catheters. They are used to remove blood clots from a main cerebral artery to restore blood flow after acute ischaemic stroke. The innovative aspects are that

Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing: Interventional procedures guidance [IPG622] – NICE

Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture. The evidence for low-intensity pulsed ultrasound

Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures [IPG623] – NICE

Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures in adults. This involves using an ultrasound probe on the skin at the site of the fracture. The evidence for low-intensity pulsed ultrasound to promote healing

Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing: Interventional procedures guidance [IPG621] – NICE

Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture. The evidence for low-intensity pulsed ultrasound

Dupilumab for treating moderate to severe atopic dermatitis: Technology appraisal guidance [TA534] – NICE

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults. Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if: the disease has not responded to at least 1 other

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs: Technology appraisal guidance [TA537] – NICE

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults. Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as described in NICE’s technology appraisal